Jupiter Neurosciences, Inc.
$0.46
▼
-2.9%
2026-04-21 07:40:01
jupiterneurosciences.com
NCM: JUNS
Explore Jupiter Neurosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$15.86 M
Current Price
$0.46
52W High / Low
$3.33 / $0.31
Stock P/E
—
Book Value
$0
Dividend Yield
—
ROCE
-73.72%
ROE
-7.39%
Face Value
—
EPS
$-0.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
—
Debt / Equity
0.05
Current Ratio
0.65
Quick Ratio
0.63
Forward P/E
6.65
Price / Sales
663.84
Enterprise Value
$16 M
EV / EBITDA
—
EV / Revenue
734.03
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 2. | Oramed Pharmaceuticals Inc. | $3.83 | 3.45 | $151.27 M | 0% | -7.12% | 37.1% | $3.96 / $1.98 | $4.98 |
| 3. | Intellia Therapeutics, Inc. | $15.21 | — | $1.8 B | — | -59.74% | -53.48% | $28.25 / $6.8 | $5.77 |
| 4. | Verastem, Inc. | $6.52 | — | $557.75 M | — | -97.68% | -14.8% | $11.24 / $4.01 | $0.74 |
| 5. | Cyclerion Therapeutics, Inc. | $3 | — | $13.08 M | — | -40.99% | -39.34% | $8.48 / $1.03 | $2.38 |
| 6. | Celcuity Inc. | $120.09 | — | $5.8 B | — | -40.76% | -1.64% | $127.34 / $9.5 | $2.08 |
| 7. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.02 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.81 M | -2.3 M | -2.26 M | -1.54 M | -1.46 M | — |
| Net Profit | -2.58 M | -2.29 M | -2.25 M | -1.53 M | -1.53 M | — |
| EPS in Rs | -0.07 | -0.06 | -0.06 | -0.04 | -0.04 | -0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.02 M | 0 M | 0 M | 0.23 M |
| Operating Profit | -8.91 M | -3.09 M | -3.87 M | -3.43 M |
| Net Profit | -8.64 M | -2.44 M | -4.78 M | -4.96 M |
| EPS in Rs | -0.24 | -0.07 | -0.13 | -0.14 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.56 M | 6.2 M | 0.15 M | 0.24 M |
| Total Liabilities | 7.4 M | 2.03 M | 5.95 M | 7.38 M |
| Equity | -1.83 M | 4.17 M | -5.8 M | -7.14 M |
| Current Assets | 4.82 M | 4.65 M | 0.03 M | 0.07 M |
| Current Liabilities | 7.4 M | 2.01 M | 5.77 M | 7.26 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.41 M | -3.91 M | -0.48 M | -1.25 M |
| Investing CF | — | — | — | — |
| Financing CF | 5.43 M | 7.65 M | 0.45 M | 0.98 M |
| Free CF | -5.41 M | -3.91 M | -0.48 M | -1.25 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 49% | 3.51% | — | — |
| Profit Margin % | — | — | -2125.15% | — |
| Operating Margin % | — | — | -1471.38% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -1807.57% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.